Health-Related Quality of Life in Sarcoidosis

Abstract

Health-related quality of life (HRQoL) describes an individual's perception of the impact of health, disease, and treatment on their quality of life (QoL). It is a reflection of how the manifestation of an illness and its treatment is personally experienced. Assessing HRQoL is particularly important in sarcoidosis because the attributable disease mortality is relatively low, and one of the major reasons for initiating treatment is to improve quality of life. HRQoL has been assessed in sarcoidosis using various generic and sarcoid-specific patient-reported outcome measures (PROMs). It is important that both the direct and indirect effects of the disease, as well as potential toxicities of therapy, are captured in the various PROMs used to assess HRQoL in sarcoidosis. This article provides a general overview of HRQoL in patients with sarcoidosis. It describes the various PROMs used to assess HRQoL in sarcoidosis and addresses the various factors that influence HRQoL in sarcoidosis. Specific attention is paid to fatigue, small fiber neuropathy, corticosteroid therapy, and other disease-specific factors that affect HRQoL in sarcoidosis. It also provides an insight into interventions that have been associated with improved HRQoL in sarcoidosis and offers suggestions for future research in this important area.

Keywords

sarcoidosis - health-related quality of life - fatigue - dyspnea - small fiber neuropathy - patient-reported outcome measures - depression - supervised exercise training program

Publication History

Article published online:
24 June 2020

• References

• 1 World Health Organization. Programme on Mental Health. Organization of Care in Psychiatry of the Elderly: A Technical Consensus Statement. Available at: https://www.who.int/mental_health/media/en/19.pdf . Accessed March 18, 2020
• 2 Swigris JJ, Gould MK, Wilson SR. Health-related quality of life among patients with idiopathic pulmonary fibrosis. Chest 2005; 127 (01) 284-294
• 3 Megari K. Quality of life in chronic disease patients. Health Psychol Res 2013; 1 (03) e27
• 4 Sprangers MA. Quality-of-life assessment in oncology. Achievements and challenges. Acta Oncol 2002; 41 (03) 229-237
• 5 Judson MA. Quality of life assessment in sarcoidosis. Clin Chest Med 2015; 36 (04) 739-750
• 6 Iannuzzi MC, Fontana JR. Sarcoidosis: clinical presentation, immunopathogenesis, and therapeutics. JAMA 2011; 305 (04) 391-399
• 7 Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med 1999; 160 (02) 736-755
• 8 Schupp JC, Freitag-Wolf S, Bargagli E. , et al. Phenotypes of organ involvement in sarcoidosis. Eur Respir J 2018; 51 (01) 51
• 9 Judson MA, Boan AD, Lackland DT. The clinical course of sarcoidosis: presentation, diagnosis, and treatment in a large white and black cohort in the United States. Sarcoidosis Vasc Diffuse Lung Dis 2012; 29 (02) 119-127
• 10 Baughman RP, Teirstein AS, Judson MA. , et al; Case Control Etiologic Study of Sarcoidosis (ACCESS) research group. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med 2001; 164 (10, Pt 1): 1885-1889
• 11 Gibson GJ, Prescott RJ, Muers MF. , et al. British Thoracic Society Sarcoidosis study: effects of long term corticosteroid treatment. Thorax 1996; 51 (03) 238-247
• 12 Baughman RP, Nunes H, Sweiss NJ, Lower EE. Established and experimental medical therapy of pulmonary sarcoidosis. Eur Respir J 2013; 41 (06) 1424-1438
• 13 McKinzie BP, Bullington WM, Mazur JE, Judson MA. Efficacy of short-course, low-dose corticosteroid therapy for acute pulmonary sarcoidosis exacerbations. Am J Med Sci 2010; 339 (01) 1-4
• 14 Baughman RP, Lower EE. Steroids for sarcoidosis: How much and for how long?. Respir Med 2018; 138S: S5-S6
• 15 Beegle SH, Barba K, Gobunsuy R, Judson MA. Current and emerging pharmacological treatments for sarcoidosis: a review. Drug Des Devel Ther 2013; 7: 325-338
• 16 Schutt AC, Bullington WM, Judson MA. Pharmacotherapy for pulmonary sarcoidosis: a Delphi consensus study. Respir Med 2010; 104 (05) 717-723
• 17 Judson MA. Corticosteroids in Sarcoidosis. Rheum Dis Clin North Am 2016; 42 (01) 119-135 , ix ix.
• 18 Khan NA, Donatelli CV, Tonelli AR. , et al. Toxicity risk from glucocorticoids in sarcoidosis patients. Respir Med 2017; 132: 9-14
• 19 Huscher D, Thiele K, Gromnica-Ihle E. , et al. Dose-related patterns of glucocorticoid-induced side effects. Ann Rheum Dis 2009; 68 (07) 1119-1124
• 20 Broos CE, Poell LHC, Looman CWN. , et al. No evidence found for an association between prednisone dose and FVC change in newly-treated pulmonary sarcoidosis. Respir Med 2018; 138S: S31-S37
• 21 Baughman RP, Iannuzzi MC, Lower EE. , et al. Use of fluticasone in acute symptomatic pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2002; 19 (03) 198-204
• 22 Grutters JC, van den Bosch JM. Corticosteroid treatment in sarcoidosis. Eur Respir J 2006; 28 (03) 627-636
• 23 Gribbin J, Hubbard RB, Le Jeune I, Smith CJ, West J, Tata LJ. Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK. Thorax 2006; 61 (11) 980-985
• 24 Reich JM. Mortality of intrathoracic sarcoidosis in referral vs population-based settings: influence of stage, ethnicity, and corticosteroid therapy. Chest 2002; 121 (01) 32-39
• 25 Swigris JJ, Olson AL, Huie TJ. , et al. Sarcoidosis-related mortality in the United States from 1988 to 2007. Am J Respir Crit Care Med 2011; 183 (11) 1524-1530
• 26 Baughman RP, Judson MA, Teirstein A. , et al. Presenting characteristics as predictors of duration of treatment in sarcoidosis. QJM 2006; 99 (05) 307-315
• 27 Baughman RP, Judson MWells A. The indications for the treatment of sarcoidosis: Wells law. Sarcoidosis Vasc Diffuse Lung Dis 2017; 34 (04) 280-282
• 28 Judson MA. The treatment of pulmonary sarcoidosis. Respir Med 2012; 106 (10) 1351-1361
• 29 Baughman RP, Barriuso R, Beyer K. , et al. Sarcoidosis: patient treatment priorities. ERJ Open Res 2018; 4 (04) 4
• 30 Cox CE, Donohue JF, Brown CD, Kataria YP, Judson MA. Health-related quality of life of persons with sarcoidosis. Chest 2004; 125 (03) 997-1004
• 31 Wirnsberger RM, de Vries J, Breteler MH, van Heck GL, Wouters EF, Drent M. Evaluation of quality of life in sarcoidosis patients. Respir Med 1998; 92 (05) 750-756
• 32 Antoniou KM, Tzanakis N, Tzouvelekis A. , et al. Quality of life in patients with active sarcoidosis in Greece. Eur J Intern Med 2006; 17 (06) 421-426
• 33 Judson MA. The three tiers of screening for sarcoidosis organ involvement. Respir Med 2016; 113: 42-49
• 34 Michielsen HJ, Drent M, Peros-Golubicic T, De Vries J. Fatigue is associated with quality of life in sarcoidosis patients. Chest 2006; 130 (04) 989-994
• 35 Aggarwal AN, Sahu KK, Gupta D. Fatigue and health-related quality of life in patients with pulmonary sarcoidosis treated by oral Corticosteroids. Sarcoidosis Vasc Diffuse Lung Dis 2016; 33 (02) 124-129
• 36 Drent M, Wirnsberger RM, Breteler MH, Kock LM, de Vries J, Wouters EF. Quality of life and depressive symptoms in patients suffering from sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 1998; 15 (01) 59-66
• 37 Chang B, Steimel J, Moller DR. , et al. Depression in sarcoidosis. Am J Respir Crit Care Med 2001; 163 (02) 329-334
• 38 Heij L, Dahan A, Hoitsma E. Sarcoidosis and pain caused by small-fiber neuropathy. Pain Res Treat 2012; 2012: 256024
• 39 Tavee J, Culver D. Sarcoidosis and small-fiber neuropathy. Curr Pain Headache Rep 2011; 15 (03) 201-206
• 40 Elfferich MD, Nelemans PJ, Ponds RW, De Vries J, Wijnen PA, Drent M. Everyday cognitive failure in sarcoidosis: the prevalence and the effect of anti-TNF-alpha treatment. Respiration 2010; 80 (03) 212-219
• 41 Drent M, Strookappe B, Hoitsma E, De Vries J. Consequences of sarcoidosis. Clin Chest Med 2015; 36 (04) 727-737
• 42 Hendriks C, Drent M, De Kleijn W, Elfferich M, Wijnen P, De Vries J. Everyday cognitive failure and depressive symptoms predict fatigue in sarcoidosis: a prospective follow-up study. Respir Med 2018; 138S: S24-S30
• 43 Judson MA. The clinical features of sarcoidosis: a comprehensive review. Clin Rev Allergy Immunol 2015; 49 (01) 63-78
• 44 Voortman M, Hendriks CMR, Elfferich MDP. , et al. The burden of sarcoidosis symptoms from a patient perspective. Hai 2019; 197 (02) 155-161
• 45 Voortman M, Hendriks CMR, Lodder P, Drent M, De Vries J. Quality of life of couples living with sarcoidosis. Respiration 2019; 98 (05) 373-382
• 46 Korenromp IHE, Heijnen CJ, Vogels OJM, van den Bosch JMM, Grutters JC. Characterization of chronic fatigue in patients with sarcoidosis in clinical remission. Chest 2011; 140 (02) 441-447
• 47 Culver D, Bjournas D, Dahan A, Brines M. Functional and symptomatic burden of small fiber neuropathy in sarcoidosis. Eur Respir J 2017; 50: PA3274
• 48 Wagner MT, Marion SD, Judson MA. The effects of fatigue and treatment with methylphenidate on sustained attention in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2005; 22 (03) 235
• 49 Parambil JG, Tavee JO, Zhou L, Pearson KS, Culver DA. Efficacy of intravenous immunoglobulin for small fiber neuropathy associated with sarcoidosis. Respir Med 2011; 105 (01) 101-105
• 50 Lower EE, Harman S, Baughman RP. Double-blind, randomized trial of dexmethylphenidate hydrochloride for the treatment of sarcoidosis-associated fatigue. Chest 2008; 133 (05) 1189-1195
• 51 Kampstra NA, Grutters JC, van Beek FT. , et al. First patient-centred set of outcomes for pulmonary sarcoidosis: a multicentre initiative. BMJ Open Respir Res 2019; 6 (01) e000394
• 52 Kampstra NA, van der Nat PB, Dijksman LM. , et al. Results of the standard set for pulmonary sarcoidosis: feasibility and multicentre outcomes. ERJ Open Res 2019; 5 (04) 5
• 53 Baughman RP, Drent M, Culver DA. , et al. Endpoints for clinical trials of sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2012; 29 (02) 90-98
• 54 Thunold RFLA, Cohen AL, Ole H. Bendstrup. Patient reported outcome measures (PROMs) in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2017; 34: 2-17
• 55 U.S. Department of Health and Human Services FDA Center for Drug Evaluation and Research; U.S. Department of Health and Human Services FDA Center for Biologics Evaluation and Research; U.S. Department of Health and Human Services FDA Center for Devices and Radiological Health. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual Life Outcomes 2006; 4: 79
• 56 Patrick DL, Burke LB, Powers JH. , et al. Patient-reported outcomes to support medical product labeling claims: FDA perspective. Value Health 2007; 10 (Suppl. 02) S125-S137
• 57 Victorson DE, Cella D, Grund H, Judson MA. A conceptual model of health-related quality of life in sarcoidosis. Qual Life Res 2014; 23 (01) 89-101
• 58 Victorson DE, Choi S, Judson MA, Cella D. Development and testing of item response theory-based item banks and short forms for eye, skin and lung problems in sarcoidosis. Qual Life Res 2014; 23 (04) 1301-1313
• 59 Gibbons CJ, Skevington SM. ; WHOQOL Group. Adjusting for cross-cultural differences in computer-adaptive tests of quality of life. Qual Life Res 2018; 27 (04) 1027-1039
• 60 Tavakol M, Dennick R. Making sense of Cronbach's alpha. Int J Med Educ 2011; 2: 53-55
• 61 Streiner DL. Starting at the beginning: an introduction to coefficient alpha and internal consistency. J Pers Assess 2003; 80 (01) 99-103
• 62 Cook CE. Clinimetrics corner: the minimal clinically important change Score (MCID): a necessary pretense. J Manual Manip Ther 2008; 16 (04) E82-E83
• 63 Jayadevappa R, Cook R, Chhatre S. Minimal important difference to infer changes in health-related quality of life-a systematic review. J Clin Epidemiol 2017; 89: 188-198
• 64 Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials 1989; 10 (04) 407-415
• 65 Bradley C. Importance of differentiating health status from quality of life. Lancet 2001; 357 (9249): 7-8
• 66 Heij L, Niesters M, Swartjes M. , et al. Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study. Mol Med 2012; 18: 1430-1436
• 67 Jastrzębski D, Ziora D, Lubecki M. , et al. Fatigue in sarcoidosis and exercise tolerance, dyspnea, and quality of life. Adv Exp Med Biol 2015; 833: 31-36
• 68 Bourbonnais JM, Malaisamy S, Dalal BD, Samarakoon PC, Parikh SR, Samavati L. Distance saturation product predicts health-related quality of life among sarcoidosis patients. Health Qual Life Outcomes 2012; 10: 67
• 69 Judson MA, Silvestri J, Hartung C, Byars T, Cox CE. The effect of thalidomide on corticosteroid-dependent pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2006; 23 (01) 51-57
• 70 Brancaleone P, Perez T, Robin S, Neviere R, Wallaert B. Clinical impact of inspiratory muscle impairment in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2004; 21 (03) 219-227
• 71 Rossman MD, Newman LS, Baughman RP. , et al. A double-blinded, randomized, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2006; 23 (03) 201-208
• 72 Bourbonnais JM, Samavati L. Effect of gender on health related quality of life in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2010; 27 (02) 96-102
• 73 Cox CE, Donohue JF, Brown CD, Kataria YP, Judson MA. The sarcoidosis health questionnaire: a new measure of health-related quality of life. Am J Respir Crit Care Med 2003; 168 (03) 323-329
• 74 Ware Jr. JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30 (06) 473-483
• 75 van Manen MJG, Wester VL, van Rossum EFC. , et al. Scalp hair cortisol and testosterone levels in patients with sarcoidosis. PLoS One 2019; 14 (06) e0215763
• 76 De Vries J, Van Heck GL, Drent M. Gender differences in sarcoidosis: symptoms, quality of life, and medical consumption. Women Health 1999; 30 (02) 99-114
• 77 Wirnsberger RM, De Vries J, Jansen TL, Van Heck GL, Wouters EF, Drent M. Impairment of quality of life: rheumatoid arthritis versus sarcoidosis. Neth J Med 1999; 54 (03) 86-95
• 78 Hoitsma E, De Vries J, van Santen-Hoeufft M, Faber CG, Drent M. Impact of pain in a Dutch sarcoidosis patient population. Sarcoidosis Vasc Diffuse Lung Dis 2003; 20 (01) 33-39
• 79 Marcellis R, Van der Veeke M, Mesters I. , et al. Does physical training reduce fatigue in sarcoidosis?. Sarcoidosis Vasc Diffuse Lung Dis 2015; 32 (01) 53-62
• 80 De Vries J, Drent M, Van Heck GL, Wouters EF. Quality of life in sarcoidosis: a comparison between members of a patient organisation and a random sample. Sarcoidosis Vasc Diffuse Lung Dis 1998; 15 (02) 183-188
• 81 Drent M, Marcellis R, Lenssen A, De Vries J. Association between physical functions and quality of life in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2014; 31 (02) 117-128
• 82 Alilović M, Peros-Golubicić T, Radosević-Vidacek B. , et al. WHOQOL-bREF questionnaire as a measure of quality of life in sarcoidosis. Coll Antropol 2013; 37 (03) 701-706
• 83 Marcellis RG, Lenssen AF, Elfferich MD. , et al. Exercise capacity, muscle strength and fatigue in sarcoidosis. Eur Respir J 2011; 38 (03) 628-634
• 84 Baughman RP, Sparkman BK, Lower EE. Six-minute walk test and health status assessment in sarcoidosis. Chest 2007; 132 (01) 207-213
• 85 Gvozdenovic BS, Mihailovic-Vucinic V, Ilic-Dudvarski A, Zugic V, Judson MA. Differences in symptom severity and health status impairment between patients with pulmonary and pulmonary plus extrapulmonary sarcoidosis. Respir Med 2008; 102 (11) 1636-1642
• 86 de Boer S, Kolbe J, Wilsher ML. The relationships among dyspnoea, health-related quality of life and psychological factors in sarcoidosis. Respirology 2014; 19 (07) 1019-1024
• 87 Gvozdenovic BS, Mihailovic-Vucinic V, Vukovic M. , et al. Effect of obesity on patient-reported outcomes in sarcoidosis. Int J Tuberc Lung Dis 2013; 17 (04) 559-564
• 88 Judson MA, Baughman RP, Costabel U. , et al. Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis. Eur Respir J 2014; 44 (05) 1296-1307
• 89 Baughman RP, Drent M, Kavuru M. , et al; Sarcoidosis Investigators. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 2006; 174 (07) 795-802
• 90 Baughman RP, Judson MA, Lower EE. , et al. Inhaled iloprost for sarcoidosis associated pulmonary hypertension. Sarcoidosis Vasc Diffuse Lung Dis 2009; 26 (02) 110-120
• 91 McHorney CA, Ware Jr. JE, Raczek AE. The MOS 36-item short-form health survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1993; 31 (03) 247-263
• 92 Patel AS, Siegert RJ, Creamer D. , et al. The development and validation of the King's sarcoidosis questionnaire for the assessment of health status. Thorax 2013; 68 (01) 57-65
• 93 Judson MA, Mack M, Beaumont JL, Watt R, Barnathan ES, Victorson DE. Validation and important differences for the sarcoidosis assessment tool. A new patient-reported outcome measure. Am J Respir Crit Care Med 2015; 191 (07) 786-795
• 94 Kosinski M, Zhao SZ, Dedhiya S, Osterhaus JT, Ware Jr JE. Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis Rheum 2000; 43 (07) 1478-1487
• 95 Swigris JJ, Brown KK, Behr J. , et al. The SF-36 and SGRQ: validity and first look at minimum important differences in IPF. Respir Med 2010; 104 (02) 296-304
• 96 Badhiwala JH, Witiw CD, Nassiri F. , et al. Minimum clinically important difference in SF-36 scores for use in degenerative cervical myelopathy. Spine 2018; 43 (21) E1260-E1266
• 97 The World Health Organization quality of life assessment (WHOQOL): development and general psychometric properties. Soc Sci Med 1998; 46 (12) 1569-1585
• 98 Den Oudsten BL, Zijlstra WP, De Vries J. The minimal clinical important difference in the World Health Organization Quality of Life instrument--100. Support Care Cancer 2013; 21 (05) 1295-1301
• 99 The WHOQOL Group. Development of the World Health Organization WHOQOL-BREF quality of life assessment. Psychol Med 1998; 28 (03) 551-558
• 100 Labor M, Pavlisa G, Alilovic M. Health-related quality of life and health status among patients with sarcoidosis, chronic obstructive pulmonary disease and interstitial lung disease. Eur Respir J 2018; 52: PA3002 ; doi:10.1183/13993003.congress-2018.PA3002
• 101 Jones PW, Quirk FH, Baveystock CM. The St George's respiratory questionnaire. Respir Med 1991; 85 (Suppl B): 25-31, discussion 33–37
• 102 Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airflow limitation. The St. George's respiratory questionnaire. Am Rev Respir Dis 1992; 145 (06) 1321-1327
• 103 Zugić V, Videnović-Ivanov J, Gvozdenović B. [St. George's respiratory questionnaire (SGRQ) in sarcoidosis patients] (in Serbian). Med Pregl 2005; 58 (Suppl. 01) 71-74
• 104 Jones PW. St. George's respiratory questionnaire: MCID. COPD 2005; 2 (01) 75-79
• 105 Jones PW. ; Nedocromil Sodium Quality of Life Study Group. Quality of life, symptoms and pulmonary function in asthma: long-term treatment with nedocromil sodium examined in a controlled multicentre trial. Eur Respir J 1994; 7 (01) 55-62
• 106 Jones PW. Interpreting thresholds for a clinically significant change in health status in asthma and COPD. Eur Respir J 2002; 19 (03) 398-404
• 107 Saligan LN, Levy-Clarke G, Wu T. , et al. Quality of life in sarcoidosis: comparing the impact of ocular and non-ocular involvement of the disease. Ophthalmic Epidemiol 2010; 17 (04) 217-224
• 108 Mangione CM, Lee PP, Pitts J, Gutierrez P, Berry S, Hays RD. ; NEI-VFQ Field Test Investigators. Psychometric properties of the national eye institute visual function questionnaire (NEI-VFQ). Arch Ophthalmol 1998; 116 (11) 1496-1504
• 109 Schiffman RM, Jacobsen G, Whitcup SM. Visual functioning and general health status in patients with uveitis. Arch Ophthalmol 2001; 119 (06) 841-849
• 110 Mangione CM, Lee PP, Gutierrez PR, Spritzer K, Berry S, Hays RD. ; National Eye Institute Visual Function Questionnaire Field Test Investigators. Development of the 25-item national eye institute visual function questionnaire. Arch Ophthalmol 2001; 119 (07) 1050-1058
• 111 Yeung H, Farber S, Birnbaum BK. , et al. Reliability and validity of cutaneous sarcoidosis outcome instruments among dermatologists, pulmonologists, and rheumatologists. JAMA Dermatol 2015; 151 (12) 1317-1322
• 112 Finlay AY, Khan GK. Dermatology life quality index (DLQI)--a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19 (03) 210-216
• 113 Pariser RJ, Paul J, Hirano S, Torosky C, Smith M. A double-blind, randomized, placebo-controlled trial of adalimumab in the treatment of cutaneous sarcoidosis. J Am Acad Dermatol 2013; 68 (05) 765-773
• 114 Rosenbach M, Yeung H, Chu EY. , et al. Reliability and convergent validity of the cutaneous sarcoidosis activity and morphology instrument for assessing cutaneous sarcoidosis. JAMA Dermatol 2013; 149 (05) 550-556
• 115 Chren MM, Lasek RJ, Flocke SA, Zyzanski SJ. Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases. Arch Dermatol 1997; 133 (11) 1433-1440
• 116 Shikiar R, Harding G, Leahy M, Lennox RD. Minimal important difference (MID) of the Dermatology Life Quality Index (DLQI): results from patients with chronic idiopathic urticaria. Health Qual Life Outcomes 2005; 3: 36
• 117 Guyatt GH, Feeny DH, Patrick DL. Measuring health-related quality of life. Ann Intern Med 1993; 118 (08) 622-629
• 118 Judson MA, Chaudhry H, Louis A, Lee K, Yucel R. The effect of corticosteroids on quality of life in a sarcoidosis clinic: the results of a propensity analysis. Respir Med 2015; 109 (04) 526-531
• 119 Dudvarski-Ilić A, Mihailović-Vucinić V, Gvozdenović B, Zugić V, Milenković B, Ilić V. Health related quality of life regarding to gender in sarcoidosis. Coll Antropol 2009; 33 (03) 837-840
• 120 De Boer S, Wilsher ML. Validation of the sarcoidosis health questionnaire in a non-US population. Respirology 2012; 17 (03) 519-524
• 121 Tanizawa K, Handa T, Nagai S. , et al. Can the sarcoidosis health questionnaire predict the long-term outcomes in Japanese sarcoidosis patients?. Respir Med 2019; 149: 1-8
• 122 Tanizawa K, Handa T, Nagai S. , et al. Validation of the Japanese version of the Sarcoidosis Health Questionnaire: a cross-sectional study. Health Qual Life Outcomes 2011; 9: 34
• 123 Van Manen MJ, Wapenaar M, Strookappe B. , et al. Validation of the King's sarcoidosis questionnaire (KSQ) in a Dutch sarcoidosis population. Sarcoidosis Vasc Diffuse Lung Dis 2016; 33 (01) 75-82
• 124 Farin E, Heyduck K, Frye BC, Birring SS, Müller-Quernheim J, Schupp JC. Translation and psychometric properties of the King's sarcoidosis questionnaire (KSQ) in German language. Health Qual Life Outcomes 2019; 17 (01) 62
• 125 Baughman RP, Sweiss N, Keijsers R. , et al. Repository corticotropin for chronic pulmonary sarcoidosis. Hai 2017; 195 (03) 313-322
• 126 Moor CC, Gür-Demirel Y, Wijsenbeek MS. Feasibility of a comprehensive home monitoring program for sarcoidosis. J Pers Med 2019; 9 (02) 9
• 127 Cho PSP, Vasudevan S, Maddocks M. , et al. Physical inactivity in pulmonary sarcoidosis. Hai 2019; 197 (03) 285-293
• 128 Mihailović-Vučinić V, Gvozdenović B, Stjepanović M. , et al. Administering the Sarcoidosis Health Questionnaire to sarcoidosis patients in Serbia. J Bras Pneumol 2016; 42 (02) 99-105
• 129 Drent M, Lower EE, De Vries J. Sarcoidosis-associated fatigue. Eur Respir J 2012; 40 (01) 255-263
• 130 Birring S, Fletcher H, Tully T, Patel A, Kullberg S, Baughman R. Standardized translation of the Kings sarcoidosis questionnaire (KSQ) into eleven languages. Am J Respir Crit Care Med 2017; 195: A4759
• 131 Patel AS, Spinou A, Keir G. , et al. Assessing sarcoidosis: The King's sarcoidosis questionnaire and the minimal important difference. Eur Respir J 2012; 40: P699
• 132 Pirozzi CS, Mendoza DL, Xu Y, Zhang Y, Scholand MB, Baughman RP. Short-term particulate air pollution exposure is associated with increased severity of respiratory and quality of life symptoms in patients with fibrotic sarcoidosis. Int J Environ Res Public Health 2018; 15 (06) 15
• 133 Gvozdenovic BS, Patel AS, Birring SS, Vucinic V. Impact of gender on disease activity, pulmonary function and health status in sarcoidosis patients - King's sarcoidosis questionnaire (KSQ). Eur Respir J 2013; 42: P413
• 134 De Kleijn WP, Elfferich MD, De Vries J. , et al. Fatigue in sarcoidosis: American versus Dutch patients. Sarcoidosis Vasc Diffuse Lung Dis 2009; 26 (02) 92-97
• 135 De Vries J, Michielsen H, Van Heck GL, Drent M. Measuring fatigue in sarcoidosis: the fatigue assessment scale (FAS). Br J Health Psychol 2004; 9 (Pt 3): 279-291
• 136 Michielsen HJ, De Vries J, Drent M, Peros-Golubicic T. Psychometric qualities of the fatigue assessment scale in Croatian sarcoidosis patients. Sarcoidosis Vasc Diffuse Lung Dis 2005; 22 (02) 133-138
• 137 Horisberger A, Courvoisier D, Ribi C. the fatigue assessment scale as a simple and reliable tool in systemic lupus erythematosus: a cross-sectional study. Arthritis Res Ther 2019; 21 (01) 80
• 138 Hendriks C, Drent M, Elfferich M, De Vries J. The fatigue assessment scale: quality and availability in sarcoidosis and other diseases. Curr Opin Pulm Med 2018; 24 (05) 495-503
• 139 Lookzadeh S, Kiani A, Taghavi K. , et al. Evaluation of the reliability and validity of the Persian version of the fatigue assessment scale in Iranian sarcoidosis patients. Open Access Maced J Med Sci 2018; 6 (07) 1310-1314
• 140 Lower EE, Malhotra A, Surdulescu V, Baughman RP. Armodafinil for sarcoidosis-associated fatigue: a double-blind, placebo-controlled, crossover trial. J Pain Symptom Manage 2013; 45 (02) 159-169
• 141 de Kleijn WP, Drent M, De Vries J. Nature of fatigue moderates depressive symptoms and anxiety in sarcoidosis. Br J Health Psychol 2013; 18 (02) 439-452
• 142 de Kleijn WP, De Vries J, Wijnen PA, Drent M. Minimal (clinically) important differences for the fatigue assessment scale in sarcoidosis. Respir Med 2011; 105 (09) 1388-1395
• 143 De Kleijn WP, Drent M, Vermunt JK, Shigemitsu H, De Vries J. Types of fatigue in sarcoidosis patients. J Psychosom Res 2011; 71 (06) 416-422
• 144 de Kleijn WP, De Vries J, Lower EE, Elfferich MD, Baughman RP, Drent M. Fatigue in sarcoidosis: a systematic review. Curr Opin Pulm Med 2009; 15 (05) 499-506
• 145 Hendriks CMR, Saketkoo LA, Elfferich MDP, De Vries J, Wijnen PAHM, Drent M. Sarcoidosis and work participation: the need to develop a disease-specific core set for assessment of work ability. Hai 2019; 197 (04) 407-413
• 146 Strookappe B, De Vries J, Elfferich M, Kuijpers P, Knevel T, Drent M. Predictors of fatigue in sarcoidosis: the value of exercise testing. Respir Med 2016; 116: 49-54
• 147 Elfferich MD, De Vries J, Drent M. Type D or ‘distressed’ personality in sarcoidosis and idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis 2011; 28 (01) 65-71
• 148 De Vries J, Drent M. Relationship between perceived stress and sarcoidosis in a Dutch patient population. Sarcoidosis Vasc Diffuse Lung Dis 2004; 21 (01) 57-63
• 149 Saligan LN. The relationship between physical activity, functional performance and fatigue in sarcoidosis. J Clin Nurs 2014; 23 (15-16): 2376-2378
• 150 De Vries J, Rothkrantz-Kos S, van Dieijen-Visser MP, Drent M. The relationship between fatigue and clinical parameters in pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2004; 21 (02) 127-136
• 151 Fleischer M, Hinz A, Brähler E, Wirtz H, Bosse-Henck A. Factors associated with fatigue in sarcoidosis. Respir Care 2014; 59 (07) 1086-1094
• 152 Hinz A, Fleischer M, Brähler E, Wirtz H, Bosse-Henck A. Fatigue in patients with sarcoidosis, compared with the general population. Gen Hosp Psychiatry 2011; 33 (05) 462-468
• 153 Kalkanis A, Yucel RM, Judson MA. The internal consistency of PRO fatigue instruments in sarcoidosis: superiority of the PFI over the FAS. Sarcoidosis Vasc Diffuse Lung Dis 2013; 30 (01) 60-64
• 154 Marcellis RG, Lenssen AF, Kleynen S, De Vries J, Drent M. Exercise capacity, muscle strength, and fatigue in sarcoidosis: a follow-up study. Hai 2013; 191 (03) 247-256
• 155 Zieleźnik K, Jastrzębski D, Ziora D. Fatigue in patients with inactive sarcoidosis does not correlate with lung ventilation ability or walking distance. Pilot Study. Pneumonol Alergol Pol 2015; 83 (01) 14-22
• 156 Hinz A, Geue K, Zenger M, Wirtz H, Bosse-Henck A. Daytime sleepiness in patients diagnosed with sarcoidosis compared with the general population. Can Respir J 2018; 2018: 6853948
• 157 Drent M, Wirnsberger RM, de Vries J, van Dieijen-Visser MP, Wouters EF, Schols AM. Association of fatigue with an acute phase response in sarcoidosis. Eur Respir J 1999; 13 (04) 718-722
• 158 Smets EM, Garssen B, Bonke B, De Haes JC. The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res 1995; 39 (03) 315-325
• 159 Michielsen HJ, Peros-Golubicic T, Drent M, De Vries J. Relationship between symptoms and quality of life in a sarcoidosis population. Respiration 2007; 74 (04) 401-405
• 160 Wirnsberger RM, de Vries J, Wouters EF, Drent M. Clinical presentation of sarcoidosis in the Netherlands an epidemiological study. Neth J Med 1998; 53 (02) 53-60
• 161 Karadallı MN, Boşnak-Güçlü M, Camcıoğlu B, Kokturk N, Türktaş H. Effects of inspiratory muscle training in subjects with sarcoidosis: a randomized controlled clinical trial. Respir Care 2016; 61 (04) 483-494
• 162 Hinz A, Brähler E, Möde R, Wirtz H, Bosse-Henck A. Anxiety and depression in sarcoidosis: the influence of age, gender, affected organs, concomitant diseases and dyspnea. Sarcoidosis Vasc Diffuse Lung Dis 2012; 29 (02) 139-146
• 163 Baydur A, Alavy B, Nawathe A, Liu S, Louie S, Sharma OP. Fatigue and plasma cytokine concentrations at rest and during exercise in patients with sarcoidosis. Clin Respir J 2011; 5 (03) 156-164
• 164 Baydur A, Alsalek M, Louie SG, Sharma OP. Respiratory muscle strength, lung function, and dyspnea in patients with sarcoidosis. Chest 2001; 120 (01) 102-108
• 165 Judson MA, Baughman RP, Costabel U. , et al; Centocor T48 Sarcoidosis Investigators. Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial. Eur Respir J 2008; 31 (06) 1189-1196
• 166 Kallianos A, Zarogoulidis P, Ampatzoglou F. , et al. Reduction of exercise capacity in sarcoidosis in relation to disease severity. Patient Prefer Adherence 2015; 9: 1179-1188
• 167 Muers MF, Middleton WG, Gibson GJ. , et al. A simple radiographic scoring method for monitoring pulmonary sarcoidosis: relations between radiographic scores, dyspnoea grade and respiratory function in the British Thoracic Society study of long-term corticosteroid treatment. Sarcoidosis Vasc Diffuse Lung Dis 1997; 14 (01) 46-56
• 168 Obi ON, Judson MA, Maier LA, Wells AU, Baughman RP. Role of baseline dyspnea index (BDI) and transition dyspnea index (TDI) as a measure of self-reported health related quality of life in sarcoidosis patients. Am J Respir Crit Care Med 2019; 199: A5609
• 169 Barros WG, Neder JA, Pereira CA, Nery LE. Clinical, radiographic and functional predictors of pulmonary gas exchange impairment at moderate exercise in patients with sarcoidosis. Respiration 2004; 71 (04) 367-373
• 170 Sweiss NJ, Noth I, Mirsaeidi M. , et al. Efficacy Results of a 52-week trial of adalimumab in the treatment of refractory sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2014; 31 (01) 46-54
• 171 Strookappe B, Elfferich M, Swigris J. , et al. Benefits of physical training in patients with idiopathic or end-stage sarcoidosis-related pulmonary fibrosis: a pilot study. Sarcoidosis Vasc Diffuse Lung Dis 2015; 32 (01) 43-52
• 172 Strookappe B, Swigris J, De Vries J, Elfferich M, Knevel T, Drent M. Benefits of Physical Training in Sarcoidosis. Hai 2015; 193 (05) 701-708
• 173 Kabitz HJ, Lang F, Walterspacher S, Sorichter S, Müller-Quernheim J, Windisch W. Impact of impaired inspiratory muscle strength on dyspnea and walking capacity in sarcoidosis. Chest 2006; 130 (05) 1496-1502
• 174 McGavin CR, Artvinli M, Naoe H, McHardy GJ. Dyspnoea, disability, and distance walked: comparison of estimates of exercise performance in respiratory disease. BMJ 1978; 2 (6132): 241-243
• 175 Fletcher CM, Elmes PC, Fairbairn AS, Wood CH. The significance of respiratory symptoms and the diagnosis of chronic bronchitis in a working population. BMJ 1959; 2 (5147): 257-266
• 176 Williams N. The MRC breathlessness scale. Occup Med (Lond) 2017; 67 (06) 496-497
• 177 Mahler DA, Wells CK. Evaluation of clinical methods for rating dyspnea. Chest 1988; 93 (03) 580-586
• 178 Mahler DA, Weinberg DH, Wells CK, Feinstein AR. The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 1984; 85 (06) 751-758
• 179 Schupp JC, Fichtner UA, Frye BC. , et al. Psychometric properties of the German version of the Leicester cough questionnaire in sarcoidosis. PLoS One 2018; 13 (10) e0205308
• 180 Tully T, Birring SS. Cough in sarcoidosis. Hai 2016; 194 (01) 21-24
• 181 Judson MA, Chopra A, Conuel E. , et al. The assessment of cough in a sarcoidosis clinic using a validated instrument and a visual analog scale. Hai 2017; 195 (05) 587-594
• 182 Sinha A, Lee KK, Rafferty GF. , et al. Predictors of objective cough frequency in pulmonary sarcoidosis. Eur Respir J 2016; 47 (05) 1461-1471
• 183 Birring SS, Prudon B, Carr AJ, Singh SJ, Morgan MD, Pavord ID. Development of a symptom specific health status measure for patients with chronic cough: Leicester cough questionnaire (LCQ). Thorax 2003; 58 (04) 339-343
• 184 Birring SS, Fleming T, Matos S, Raj AA, Evans DH, Pavord ID. The Leicester Cough Monitor: preliminary validation of an automated cough detection system in chronic cough. Eur Respir J 2008; 31 (05) 1013-1018
• 185 Spinou A, Birring SS. An update on measurement and monitoring of cough: what are the important study endpoints?. J Thorac Dis 2014; 6 (Suppl. 07) S728-S734
• 186 Korenromp IH, Grutters JC, van den Bosch JM, Zanen P, Kavelaars A, Heijnen CJ. Reduced Th2 cytokine production by sarcoidosis patients in clinical remission with chronic fatigue. Brain Behav Immun 2011; 25 (07) 1498-1502
• 187 Korenromp IH, Grutters JC, van den Bosch JM, Heijnen CJ. Post-inflammatory fatigue in sarcoidosis: personality profiles, psychological symptoms and stress hormones. J Psychosom Res 2012; 72 (02) 97-102
• 188 Wirnsberger RM, Drent M, Hekelaar N. , et al. Relationship between respiratory muscle function and quality of life in sarcoidosis. Eur Respir J 1997; 10 (07) 1450-1455
• 189 Atkins C, Wilson AM. Managing fatigue in sarcoidosis - a systematic review of the evidence. Chron Respir Dis 2017; 14 (02) 161-173
• 190 Judson MA. Quality of life in sarcoidosis. Semin Respir Crit Care Med 2017; 38 (04) 546-558
• 191 Lal C, Medarov BI, Judson MA. Interrelationship between sleep-disordered breathing and sarcoidosis. Chest 2015; 148 (04) 1105-1114
• 192 Pietinalho A, Ohmichi M, Hiraga Y, Löfroos AB, Selroos O. The mode of presentation of sarcoidosis in Finland and Hokkaido, Japan. A comparative analysis of 571 Finnish and 686 Japanese patients. Sarcoidosis Vasc Diffuse Lung Dis 1996; 13 (02) 159-166
• 193 Laitinen LA, Haahtela T, Kava T, Laitinen A. Non-specific bronchial reactivity and ultrastructure of the airway epithelium in patients with sarcoidosis and allergic alveolitis. Eur J Respir Dis Suppl 1983; 131: 267-284
• 194 Marcias S, Ledda MA, Perra R, Severino C, Rosetti L. Aspecific bronchial hyperreactivity in pulmonary sarcoidosis. Sarcoidosis 1994; 11 (02) 118-122
• 195 Ohrn MB, Sköld CM, van Hage-Hamsten M, Sigurdardottir O, Zetterström O, Eklund A. Sarcoidosis patients have bronchial hyperreactivity and signs of mast cell activation in their bronchoalveolar lavage. Respiration 1995; 62 (03) 136-142
• 196 Lewis MM, Mortelliti MP, Yeager Jr. H, Tsou E. Clinical bronchiectasis complicating pulmonary sarcoidosis: case series of seven patients. Sarcoidosis Vasc Diffuse Lung Dis 2002; 19 (02) 154-159
• 197 Curtis JR, Borson S. Examining the link between sarcoidosis and depression. Am J Respir Crit Care Med 2001; 163 (02) 306-308
• 198 Bakkers M, Merkies IS, Lauria G. , et al. Intraepidermal nerve fiber density and its application in sarcoidosis. Neurology 2009; 73 (14) 1142-1148
• 199 Hoitsma E, Marziniak M, Faber CG. , et al. Small fibre neuropathy in sarcoidosis. Lancet 2002; 359 (9323): 2085-2086
• 200 Tavee JO, Karwa K, Ahmed Z, Thompson N, Parambil J, Culver DA. Sarcoidosis-associated small fiber neuropathy in a large cohort: Clinical aspects and response to IVIG and anti-TNF alpha treatment. Respir Med 2017; 126: 135-138
• 201 Culver DA, Dahan A, Bajorunas D. , et al. Cibinetide improves corneal nerve fiber abundance in patients with sarcoidosis-associated small nerve fiber loss and neuropathic pain. Invest Ophthalmol Vis Sci 2017; 58 (06) BIO52-BIO60
• 202 Quattrini C, Tavakoli M, Jeziorska M. , et al. Surrogate markers of small fiber damage in human diabetic neuropathy. Diabetes 2007; 56 (08) 2148-2154
• 203 Hoitsma E, De Vries J, Drent M. The small fiber neuropathy screening list: Construction and cross-validation in sarcoidosis. Respir Med 2011; 105 (01) 95-100
• 204 Hoitsma E, Faber CG, van Santen-Hoeufft M, De Vries J, Reulen JP, Drent M. Improvement of small fiber neuropathy in a sarcoidosis patient after treatment with infliximab. Sarcoidosis Vasc Diffuse Lung Dis 2006; 23 (01) 73-77
• 205 Dahan A, Dunne A, Swartjes M. , et al. ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density. Mol Med 2013; 19: 334-345
• 206 van Velzen M, Heij L, Niesters M. , et al. ARA 290 for treatment of small fiber neuropathy in sarcoidosis. Expert Opin Investig Drugs 2014; 23 (04) 541-550
• 207 Pilzak K, Zebrowska A, Sikora M. , et al. Physical functioning and symptoms of chronic fatigue in sarcoidosis patients. Adv Exp Med Biol 2018; 1040: 13-21
• 208 Naz I, Ozalevli S, Ozkan S, Sahin H. Efficacy of a structured exercise program for improving functional capacity and quality of life in patients with stage 3 and 4 sarcoidosis: a randomized controlled trial. J Cardiopulm Rehabil Prev 2018; 38 (02) 124-130
• 209 Kaiser CA, Cozzio A, Hofbauer GF, Kamarashev J, French LE, Navarini AA. Disfiguring annular sarcoidosis improved by adalimumab. Case Rep Dermatol 2011; 3 (02) 103-106
• 210 Bosse-Henck A, Wirtz H, Hinz A. Subjective sleep quality in sarcoidosis. Sleep Med 2015; 16 (05) 570-576
• 211 Makambi KH, Williams CD, Taylor TR, Rosenberg L, Adams-Campbell LL. An assessment of the CES-D scale factor structure in black women: The Black Women's Health Study. Psychiatry Res 2009; 168 (02) 163-170
• 212 Bosse-Henck A, Koch R, Wirtz H, Hinz A. Fatigue and excessive daytime sleepiness in sarcoidosis: prevalence, predictors, and relationships between the two symptoms. Respiration 2017; 94 (02) 186-197
• 213 Holas P, Krejtz I, Urbankowski T, Skowyra A, Ludwiniak A, Domagala-Kulawik J. Anxiety, its relation to symptoms severity and anxiety sensitivity in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2013; 30 (04) 282-288
• 214 Baughman P, Birring S, Judson MA. , et al. A double blind, placebo controlled study of roflumilast to prevent acute events in fibrotic sarcoidosis. Am J Respir Crit Care Med 2017; 195: A4752